Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Long-Term Investments (2018 - 2022)

Arcturus Therapeutics Holdings (ARCT) has disclosed Long-Term Investments for 5 consecutive years, with $131000.0 as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Long-Term Investments fell 89.5% year-over-year to $131000.0, compared with a TTM value of $131000.0 through Mar 2022, down 89.5%, and an annual FY2021 reading of $515000.0, changed N/A over the prior year.
  • Long-Term Investments was $131000.0 for Q1 2022 at Arcturus Therapeutics Holdings, down from $515000.0 in the prior quarter.
  • Across five years, Long-Term Investments topped out at $1.2 million in Q1 2021 and bottomed at $100000.0 in Q1 2020.
  • Average Long-Term Investments over 5 years is $493111.1, with a median of $303000.0 recorded in 2019.
  • The sharpest move saw Long-Term Investments surged 1148.0% in 2021, then plummeted 89.5% in 2022.
  • Year by year, Long-Term Investments stood at $288000.0 in 2018, then decreased by 8.68% to $263000.0 in 2019, then crashed by 61.98% to $100000.0 in 2020, then surged by 415.0% to $515000.0 in 2021, then tumbled by 74.56% to $131000.0 in 2022.
  • Business Quant data shows Long-Term Investments for ARCT at $131000.0 in Q1 2022, $515000.0 in Q4 2021, and $670000.0 in Q3 2021.